Sheryl Stevenson
Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of Ophthalmology Times for more than 20 years. As Group Editorial Director, Sheryl’s purview extends across the print and digital network of Ophthalmology Times, Ophthalmology Times Europe, Modern Retina and Optometry Times. Prior to ophthalmology, Sheryl previously covered the fields of audiology and confectionery science/technology/manufacturing.
Sheryl is also passionate about the mission, vision and values of Ophthalmic World Leaders (OWL) and recently completed her term on its Board of Directors. She continues to volunteer as Editor-in-Chief of the organization’s EMPOWER Magazine. In 2013, she was honored with the group’s inaugural Rising Star Award.
In addition, she has served as a judge for Crain's Cleveland Business Health Care Heroes Awards program as well as the Jesse H. Neal National Business Journalism Awards.
Articles
High-tech, noninvasive imaging identifies early glaucoma
August 6th 2022Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study. This measurement could potentially be used as a first-line indicator to monitor of glaucoma progression for the patient and the physician.
Hypersonic vitrectomy a novel technology for removing vitreous
June 29th 2022Though the speed of traditional guillotine cutters has increased significantly in recent years, there are certain limitations. With the advent of hypersonic vitrectomy, Dr Sunir J. Garg explains how retinal surgeons can remove the vitreous gel with more efficiency.
Significance of the YOSEMITE and RHINE 2-year DMO clinical trial results
June 28th 2022In the study, the faricimab molecule, which is a combined anti-Ang2 and anti-VEGF, performed better than the aflibercept drug in many different ways. Rishi P. Singh, MD, FASRS, summarizes some of these key findings.
Blocking Connexin-43 may improve diabetic retinopathy, AMD
February 11th 2022Dr David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.
